Mary Welch, MD is an Assistant Professor of Neurology at CUMC, in the Division of Neuro-Oncology. Dr. Welch graduated from Chicagos' Northwestern Feinberg School of Medicine. She completed neurology residency here at Columbia, followed by sub-specialty training in neuro-oncology at Memorial Sloan-Kettering Cancer Center. In her second year of fellowship, she earned a Comparative Effectiveness Research Award to attend Columbia's Summer Research Institute at Mailman School of Public Health.
Upon completing her training, Dr. Welch worked for several years as a practicing neuro-oncologist and Assistant Professor of Neurology at Montefiore Medical Center in the Bronx. There, she served as principal investigator for numerous phase I and II clinical trials for the treatment of primary and metastatic brain cancer. She also developed a strong research interest in improving patient access to both standard and investigational therapies. In addition to seeing both inpatient and outpatient neuro-oncology patients, Dr. Welch maintains an active research program within the Division of Neuro-Oncology.
|Brain Tumors||[ CLOSED ] INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)|
|Brain Tumors||[ CLOSED ] Study of DSP-7888 in Combination with Bevacizumab in Patients with Recurrent or Progressive Glioblastoma|
|Neurological Disorders||Collection of Tissue and Medical Information from Research Subjects with Neurological Disorders|
|Brain Tumors||[ CLOSED ] Study Treatment (INO-5401 and INO-9012 delivered by electoporation device in combination with REGN2810) in Subjects with Glioblastoma|
|Brain Tumors||[ CLOSED ] Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with High-Grade Glioma (HGG)|
|Brain Tumors||[ CLOSED ] Study of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma|
|Cancer||[ CLOSED ] CB-839 With Radiation Therapy and Temozolomide in Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma|
|Brain Tumors||Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma|
|Brain Cancer||Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma|